BioStock: Aptahem's Chairman of the Board on the latest news

Biotechnology company Aptahem, which is developing the preclinical drug candidate Apta-1 for the treatment of sepsis, recently announced that it has suspended the exclusive negotiating period with the unnamed pharmaceutical company regarding Apta-1 that it entered in March. BioStock got in touch with the Company's Chairman of the Board, Bert Junno, for a comment.

Read the full interview with Bert Junno at biostock.se:

https://www.biostock.se/en/aptahems-chairman-of-the-board-on-the-latest-news/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se